NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Price, News & Analysis $1.84 -0.07 (-3.66%) Closing price 05/21/2025 03:59 PM EasternExtended Trading$1.90 +0.06 (+3.26%) As of 05/21/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bluejay Diagnostics Stock (NASDAQ:BJDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bluejay Diagnostics alerts:Sign Up Key Stats Today's Range$1.77▼$1.9450-Day Range$1.64▼$7.5052-Week Range$1.46▼$316.92Volume75,967 shsAverage Volume493,270 shsMarket Capitalization$1.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Read More… Bluejay Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreBJDX MarketRank™: Bluejay Diagnostics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bluejay Diagnostics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bluejay Diagnostics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bluejay Diagnostics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBluejay Diagnostics has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.36% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently increased by 147.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBluejay Diagnostics does not currently pay a dividend.Dividend GrowthBluejay Diagnostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.36% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently increased by 147.26%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for BJDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.37% of the stock of Bluejay Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 18.47% of the stock of Bluejay Diagnostics is held by institutions.Read more about Bluejay Diagnostics' insider trading history. Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address BJDX Stock News HeadlinesBluejay Diagnostics Inc BJDXMay 13, 2025 | morningstar.comBluejay Diagnostics announces abstract acceptance at 2025 SAEM meetingApril 15, 2025 | markets.businessinsider.comWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don't even pay dividends. It's fast, it's legal, and most people have no clue it exists.May 22, 2025 | Investors Alley (Ad)Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual MeetingApril 15, 2025 | globenewswire.comBluejay Diagnostics Raises $3.7M Through Warrant Deal, Stock Slides After-Hours While Retail Interest SurgesApril 8, 2025 | msn.comBluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross ProceedsApril 7, 2025 | globenewswire.comBluejay Diagnostics Inc trading halted, news pendingNovember 16, 2024 | markets.businessinsider.comBluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Reverse Stock SplitNovember 14, 2024 | finanznachrichten.deSee More Headlines BJDX Stock Analysis - Frequently Asked Questions How have BJDX shares performed this year? Bluejay Diagnostics' stock was trading at $4.87 on January 1st, 2025. Since then, BJDX shares have decreased by 62.2% and is now trading at $1.84. View the best growth stocks for 2025 here. How were Bluejay Diagnostics' earnings last quarter? Bluejay Diagnostics, Inc. (NASDAQ:BJDX) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($3.37) earnings per share for the quarter. When did Bluejay Diagnostics' stock split? Bluejay Diagnostics shares reverse split before market open on Thursday, June 20th 2024. The 1-8 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Bluejay Diagnostics IPO? Bluejay Diagnostics (BJDX) raised $22 million in an initial public offering (IPO) on Wednesday, November 10th 2021. The company issued 2,160,000 shares at a price of $10.00 per share. How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bluejay Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bluejay Diagnostics investors own include SoFi Technologies (SOFI), Athenex (ATNX), VF (VFC), Allarity Therapeutics (ALLR), Andersons (ANDE) and British American Tobacco (BTI). Company Calendar Last Earnings5/13/2025Today5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:BJDX CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($379.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-155.67% Return on Assets-117.82% Debt Debt-to-Equity RatioN/A Current Ratio6.26 Quick Ratio6.26 Sales & Book Value Annual Sales$250,000.00 Price / Sales4.08 Cash FlowN/A Price / Cash FlowN/A Book Value$934.50 per share Price / Book0.00Miscellaneous Outstanding Shares554,000Free Float551,000Market Cap$1.02 million OptionableNot Optionable Beta0.40 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:BJDX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.